Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06872333 · ClinicalTrials.gov registry record · Phase 2
Allo HSCT for High Risk Hemoglobinopathies
A Phase 2 study of Sickle Cell Disease and Hemoglobinopathies, sponsored by Masonic Cancer Center, University of Minnesota.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT06872333: Recruiting Phase 2 study of Sickle Cell Disease and Hemoglobinopathies, sponsored by Masonic Cancer Center, University of Minnesota.
NCT06872333 is a Phase 2 study of Sickle Cell Disease and Hemoglobinopathies that is actively recruiting participants, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 62 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06872333, a Phase 2 study of Sickle Cell Disease and Hemoglobinopathies, is actively recruiting participants, sponsored by Masonic Cancer Center, University of Minnesota.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Alemtuzumab
- DRUG Thymoglobulin
- RADIATION Total Body Irradiation
- BIOLOGICAL Cell Infusion
Study Locations (1)
Minnesota
- Masonic Cancer Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2024-11-19 |
| Est. Completion | 2032-06-01 |
| Phase | Phase 2 |
What NCT06872333 shows while recruiting
NCT06872333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (79% lower).
The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 5 interventions - of which Fludarabine is the first listed.
NCT06872333 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06872333 about?
NCT06872333 is a clinical study titled "Allo HSCT for High Risk Hemoglobinopathies". A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
What is the current status of trial NCT06872333?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2024-11-19. Estimated completion is 2032-06-01.
What conditions does trial NCT06872333 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Hemoglobinopathies, Graft Failure.
What interventions are being tested in trial NCT06872333?
The interventions under investigation include: Fludarabine (DRUG), Alemtuzumab (DRUG), Thymoglobulin (DRUG), Total Body Irradiation (RADIATION), Cell Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT06872333?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06872333 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06872333's enrollment target sits among peer trials
62 92nd of 213 higher than 122 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI